Engineered Phagemids for Nonlytic, Targeted Antibacterial Therapies

Engineered Phagemids for Nonlytic, Targeted Antibacterial Therapies

The increasing incidence of antibiotic-resistant bacterial infections is creating a global public health threat. Because conventional antibiotic drug discovery has failed to keep pace with the rise of resistance, a growing need exists to develop novel antibacterial methodologies. Replication-compete...

Full description

Bibliographic Details
Main Authors: Krom, Russell-John (Contributor), Saluja, Prerna (Contributor), Lobritz, Michael Andrew (Contributor), Collins, James J. (Contributor)
Other Authors: Institute for Medical Engineering and Science (Contributor), MIT Synthetic Biology Center (Contributor), Broad Institute of MIT and Harvard (Contributor), Massachusetts Institute of Technology. Department of Biological Engineering (Contributor), Collins, James (Contributor)
Format: Article
Language:English
Published: American Chemical Society (ACS), 2017-05-03T14:16:47Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items